Read by QxMD icon Read


K J Dal Prá, C A A Lemos, R Okamoto, A M P Soubhia, E P Pellizzer
This systematic review evaluated the efficacy of the morning fasting serum C-terminal telopeptide (CTX) test in predicting the development of bisphosphonate-related osteonecrosis of the jaw (BRONJ). A comprehensive search of studies published up to March 2016, and listed in the PubMed/MEDLINE, Web of Science, and Cochrane Library databases, was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. This review has been registered in the PROSPERO international prospective register of systematic reviews (CRD42016036717)...
November 19, 2016: International Journal of Oral and Maxillofacial Surgery
Seung Jae Paek, Won-Jong Park, Ho-Sung Shin, Moon-Gi Choi, Kyung-Hwan Kwon, Eun Joo Choi
OBJECTIVES: The objective of this study was to retrospectively investigate the association of diseases having an influence on inhibition of angiogenesis such as hypertension, diabetes mellitus type II, hypercholesterolemia, and rheumatoid arthritis (RA) with the development of osteonecrosis of the jaws. MATERIALS AND METHODS: The 135 patients were allocated into 4 groups of bisphosphonate-related osteonecrosis of the jaw (BRONJ) group (1A); non-BRONJ group (1B); osteonecrosis of the jaw (ONJ) group (2A); and control group (2B), according to histologic results and use of bisphosphonate...
October 2016: Journal of the Korean Association of Oral and Maxillofacial Surgeons
Hye-Yeon Kim, Jin-Woo Kim, Sun-Jong Kim, Sang-Hwa Lee, Hong-Soo Lee
To assess the relevance of previous epidemiologic studies on bisphosphonate-related osteonecrosis of the jaw (BRONJ), we first conducted a systematic review of large population-based observational studies, and evaluated the validity of claims-based algorithms for the identification of BRONJ. Studies containing primary observational epidemiologic data regarding bisphosphonate exposure and outcomes of osteonecrosis of the jaw were systematically reviewed. Using surrogates for identifying potential BRONJ cases from a population-based hospital registry, validation was performed through medical chart review...
October 13, 2016: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
M Pedrazzoli, L Autelitano, F Biglioli
Mandibular fracture is usually the clinical end of bisphosphonate-related osteonecrosis of the jaw. This is a painful complication and patients cannot feed as usual, with a worsening of their quality of life. The goal of treatment in bisphosphonate related osteonecrosis of jaw (BRONJ) patients is to slow progression of bone necrosis. We present a novel technique for treatment of severe mandibular BRONJ in stage 3 patients that present with a high risk to develop fracture, since they have a residual unaffected mandibular bone height less than 6 mm...
August 2016: Acta Otorhinolaryngologica Italica
Yong-Dae Kwon, Chae-Yoon Lee, Sung Ok Hong, Yeon-Ah Lee, Joo-Young Ohe, Deog-Yoon Kim
BACKGROUND: The purpose of this study was to describe the clinical characteristics of bisphosphonate related osteonecrosis of the jaws (BRONJ) in osteoporotic males. METHODS: The medical records of BRONJ patients from 2007 to 2014 were reviewed. The data from only the male patients was extracted, and demographic data was collected and biochemical markers were measured. RESULTS: 11 Patients out of 210 (5 %) being males. Among the 11 patients, the indication of bisphosphonate (BP) was osteoporosis in 9 patients, and cancer in two...
2016: SpringerPlus
Mohammed Qaisi, Jamie Hargett, Matthew Loeb, Jeffrey Brown, Ronald Caloss
Bisphosphonates have been used for years in the treatment of patients with distant bony metastasis and in the prevention of osteoporosis. One of main side effects of these medications is the development of bisphosphonate related osteonecrosis of the jaw (BRONJ) in a small subset of patients. A new class of medications with a shorter half-life, known as receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors, was introduced with the hopes of avoiding this side effect. However, reports of osteonecrosis of the jaw after the use of RANKL inhibitors have also been documented...
2016: Case Reports in Dentistry
Minju Song, Abdullah Alshaikh, Terresa Kim, Sol Kim, Michelle Dang, Shebli Mehrazarin, Ki-Hyuk Shin, Mo Kang, No-Hee Park, Reuben H Kim
INTRODUCTION: Surgical interventions such as tooth extraction increase the chances of developing osteonecrosis of the jaw in patients receiving bisphosphonates (BPs) for the treatment of bone-related diseases. Tooth extraction is often performed to eliminate preexisting pathological inflammatory conditions that make the tooth unsalvageable; however, the role of such conditions on bisphosphonate-related osteonecrosis of the jaw (BRONJ) development after tooth extraction is not clearly defined...
November 2016: Journal of Endodontics
Jin-Woo Kim, Su-Ra Jeong, Sun-Jong Kim, YeonSoo Kim
BACKGROUND: This study aimed to investigate medical doctors' awareness of bisphosphonate-related osteonecrosis of the jaw (BRONJ) and the status of dental referrals. METHODS: Self-administered questionnaires were distributed to medical doctors practicing internal medicine, family medicine, and orthopedics at the 6 tertiary medical centers located in Seoul, Korea. The survey consisted of 22 questions regarding the general characteristics, bisphosphonate therapy, awareness of BRONJ, and implementation of dental referrals...
September 7, 2016: BMC Oral Health
Tae-Hwan Kim, Won-Gyo Seo, Chul-Hong Koo, Jae-Hoon Lee
OBJECTIVES: This study examined the statistical relevance of whether the systemic predisposing factors affect the prognosis of surgical treatment of bisphosphonate-related osteonecrosis of the jaw (BRONJ). All cases had undergone bone biopsies to determine the characteristics of the mechanisms of BRONJ by optical microscopy. MATERIALS AND METHODS: The data included 54 BRONJ cases who underwent surgery and in whom bone biopsies were performed. The results of surgery were evaluated and the results were classified into 3 categories: normal recovery, delayed recovery, and recurrence after surgery...
August 2016: Journal of the Korean Association of Oral and Maxillofacial Surgeons
Takefumi Oizumi, Kouji Yamaguchi, Koichiro Sato, Masato Takahashi, Gen Yoshimura, Hiroshi Otsuru, Masahiro Tsuchiya, Yoshihiro Hagiwara, Eiji Itoi, Shunji Sugawara, Tetsu Takahashi, Yasuo Endo
Bisphosphonate (BP)-related osteonecrosis of the jaw (BRONJ) can occur when enhanced bone-resorptive diseases are treated with nitrogen-containing BPs (N-BPs). Having previously found, in mice, that the non-N-BP etidronate can (i) reduce the inflammatory/necrotic effects of N-BPs by inhibiting their intracellular entry and (ii) antagonize the binding of N-BPs to bone hydroxyapatite, we hypothesized that etidronate-replacement therapy (Eti-RT) might be useful for patients with, or at risk of, BRONJ. In the present study we examined this hypothesis...
2016: Biological & Pharmaceutical Bulletin
Sol Kim, Drake W Williams, Cindy Lee, Terresa Kim, Atsushi Arai, Songtao Shi, Xinmin Li, Ki-Hyuk Shin, Mo K Kang, No-Hee Park, Reuben H Kim
Long-term administration of nitrogen-containing bisphosphonates can induce detrimental side effects such as bisphosphonate-related osteonecrosis of the jaw (BRONJ) in human. Although inflammation is known to be associated with BRONJ development, the detailed underlying mechanism remains unknown. Here, we report that the pro-inflammatory cytokine IL-36α is, in part, responsible for the BRONJ development. We found a notably higher level of IL-36α and lower level of collagen in the BRONJ lesions in mice. We also found that IL-36α remarkably suppressed TGF-β-mediated expression of Collα1 and α-Sma via the activation of Erk signaling pathway in mouse gingival mesenchymal stem cells...
August 27, 2016: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
Thomas Mücke, Herbert Deppe, Jana Hein, Klaus-Dietrich Wolff, David A Mitchell, Marco R Kesting, Margitta Retz, Jürgen E Gschwend, Mark Thalgott
INTRODUCTION: To explore the preventive effect of a prophylactic oral and maxillofacial treatment to reduce bisphosphonate associated necrosis of the jaws (BRONJ) in metastatic prostate cancer (PC) patients treated with zoledronic acid (4.0 mg i.v./months). MATERIALS AND METHOD: 253 PC patients with bone metastases were prospectively randomized. All patients received baseline assessments including a dental panoramic tomogram. Group A was monitored and treated where deemed necessary by the patient's dentist and were re-evaluated once a year...
August 2, 2016: Journal of Cranio-maxillo-facial Surgery
Bruce Turner, Lawrence Drudge-Coates, Sacha Ali, Jhumur Pati, Vinod Nargund, Enamul Ali, Leo Cheng, Paula Wells
Urologic patients receiving bone-targeted therapies are at risk of developing osteonecrosis of the jaw (ONJ). ONJ has historically been associated with bisphosphonate therapy. More recently, RANK-Ligand inhibitors (denosumab) have also been used to reduce the risk of skeletal-related events in patients who have advanced cancers with bone metastases. More than 65% of men with metastatic prostate cancer and nearly 75% of women with metastatic breast cancer are affected by bone metastases. The literature has described ONJ associated with bisphosphonate therapy as bisphosphonate-related osteonecrosis of the jaw (BRONJ)...
May 2016: Urologic Nursing
Y-X Guo, G Misra, C-B Guo, J-G An
We describe the reconstruction of a mandible damaged by bisphosphonate-related osteonecrosis of the jaw (BRONJ) using the simple and safe combination of a reconstruction plate and patching with a submandibular gland.
October 2016: British Journal of Oral & Maxillofacial Surgery
Larry Weeda
No abstract text is available yet for this article.
September 2016: Cranio: the Journal of Craniomandibular Practice
N-R de-Freitas, L-B Lima, M-B de-Moura, C-C-F Veloso-Guedes, P-C Simamoto-Júnior, D de-Magalhães
BACKGROUND: To analyze articles that studied patients submitted to diphosphonates therapy and who received dental implants before, during or after bisphosphonate (BP) treatment, compared to healthy patients, analyzing the increase of failure and loss of implants or bisphosphonate related osteonecrosis of the jaw (BRONJ) incidence. MATERIAL AND METHODS: The Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement was used in this study...
2016: Medicina Oral, Patología Oral y Cirugía Bucal
Russell Lain, Shilpi Ajwani
BACKGROUND: Oral bisphosphonates (BP) have been prescribed widely in osteoporosis patients. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) has been reported as a major complication, but there is little information about minor complications. OBJECTIVE: This retrospective study describes post-operative complications - other than BRONJ - associated with dental extractions in patients on oral BP and compares outcomes with patients not on oral BP. METHODS: The study period was 2004-05 ending December 2005, prior to the introduction of protocols for minimising risks related to extractions in patients on BP therapy...
July 19, 2016: Gerodontology
Ji-Wan Kim, Jin Baik, Ju-Hong Jeon
Although pathophysiology, incidence, and factors associated with the development of bisphosphonate-related osteonecrosis of the jaw (BRONJ) and management strategies for patients treated with bisphosphonates or patients with BRONJ are well-established, few guidelines or recommendations are available for patients with a history of successfully healed BRONJ. We present a case of successful dental implant treatment after healing of BRONJ in the same region of the jaw, and speculate that implant placement is possible after healing of BRONJ surgery in select cases...
June 2016: Journal of the Korean Association of Oral and Maxillofacial Surgeons
Mehmet Fatih Senturk, Emre Cimen, Aysegul Mine Tuzuner Oncul, Mine Cambazoglu
OBJECTIVE: To evaluate the oncologists thoughts about the positive and adverse effects of bisphosphonates, drug holiday and the awareness about BRONJ. METHODS: A written questionnaire was sent to 7 hospitals, which have oncology facilities in Ankara, Turkey. Results were evaluated as percentages. Chi Square and Kruskal Wallis H test was used to analyze the data. RESULTS: A total of 53 oncologists replied to the questionnaire. BRONJ is the most seen complication (66%) due to bisphosphonates usage...
July 2016: JPMA. the Journal of the Pakistan Medical Association
Sarina E C Pichardo, Sophie C C Kuijpers, J P Richard van Merkesteyn
INTRODUCTION: Bisphosphonates are used in the treatment of osteoporosis and bone metastases. They inhibit osteoclast function, thereby decreasing bone resorption. A side effect of these drugs is bisphosphonate-related osteonecrosis of the jaw (BRONJ), which can be difficult to treat. The purpose of this study was to evaluate the surgical treatment protocol used in our hospital for BRONJ patients. The patients were retrospectively analyzed and followed-up at the Leiden University Medical Center...
September 2016: Journal of Cranio-maxillo-facial Surgery
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"